Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease

Shoji Yamanaka, Mark D. Johnson, Alex Grinberg, Heiner Westphal, Jacqueline Crawley, Masako Taniike, Kinuko Suzuki, Richard L. Proia

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

Tay-Sachs disease, the prototype of the G(M2) gangliosidoses, is a catastrophic neurodegenerative disorder of infancy. The disease is caused by mutations in the HEXA gene resulting in an absence of the lysosomal enzyme, β-hexosaminidase A. As a consequence of the enzyme deficiency, G(M2) ganglioside accumulates progressively, beginning early in fetal life, to excessive amounts in the central nervous system. Rapid mental and motor deterioration starting in the first year of life leads to death by 2-4 years of age. Through the targeted disruption of the mouse Hexa gene in embryonic stem cells, we have produced mice with biochemical and neuropathologic features of Tay-Sachs disease. The mutant mice displayed <1% of normal β- hexosaminidase A activity and accumulated G(M2) ganglioside in their central nervous system in an age-dependent manner. The accumulated ganglioside was stored in neurons as membranous cytoplasmic bodies characteristically found in the neurons of Tay-Sachs disease patients. At 3-5 months of age, the mutant mice showed no apparent defects in motor or memory function. These β- hexosaminidase A-deficient mice should be useful for devising strategies to introduce functional enzyme and genes into the central nervous system. This model may also be valuable for studying the biochemical and pathologic changes occurring during the course of the disease.

Original languageEnglish (US)
Pages (from-to)9975-9979
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume91
Issue number21
DOIs
StatePublished - Oct 11 1994
Externally publishedYes

Fingerprint

Tay-Sachs Disease
Hexosaminidase A
G(M2) Ganglioside
Central Nervous System
Genes
GM2 Gangliosidosis
Enzymes
Neurons
Gangliosides
Embryonic Stem Cells
Neurodegenerative Diseases
Mutation

Keywords

  • animal model
  • G(M2) gangliosidosis
  • homologous recombination
  • lysosomal storage disease

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease. / Yamanaka, Shoji; Johnson, Mark D.; Grinberg, Alex; Westphal, Heiner; Crawley, Jacqueline; Taniike, Masako; Suzuki, Kinuko; Proia, Richard L.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 91, No. 21, 11.10.1994, p. 9975-9979.

Research output: Contribution to journalArticle

Yamanaka, Shoji ; Johnson, Mark D. ; Grinberg, Alex ; Westphal, Heiner ; Crawley, Jacqueline ; Taniike, Masako ; Suzuki, Kinuko ; Proia, Richard L. / Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease. In: Proceedings of the National Academy of Sciences of the United States of America. 1994 ; Vol. 91, No. 21. pp. 9975-9979.
@article{dfb8555dea5342359529411524475dcb,
title = "Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease",
abstract = "Tay-Sachs disease, the prototype of the G(M2) gangliosidoses, is a catastrophic neurodegenerative disorder of infancy. The disease is caused by mutations in the HEXA gene resulting in an absence of the lysosomal enzyme, β-hexosaminidase A. As a consequence of the enzyme deficiency, G(M2) ganglioside accumulates progressively, beginning early in fetal life, to excessive amounts in the central nervous system. Rapid mental and motor deterioration starting in the first year of life leads to death by 2-4 years of age. Through the targeted disruption of the mouse Hexa gene in embryonic stem cells, we have produced mice with biochemical and neuropathologic features of Tay-Sachs disease. The mutant mice displayed <1{\%} of normal β- hexosaminidase A activity and accumulated G(M2) ganglioside in their central nervous system in an age-dependent manner. The accumulated ganglioside was stored in neurons as membranous cytoplasmic bodies characteristically found in the neurons of Tay-Sachs disease patients. At 3-5 months of age, the mutant mice showed no apparent defects in motor or memory function. These β- hexosaminidase A-deficient mice should be useful for devising strategies to introduce functional enzyme and genes into the central nervous system. This model may also be valuable for studying the biochemical and pathologic changes occurring during the course of the disease.",
keywords = "animal model, G(M2) gangliosidosis, homologous recombination, lysosomal storage disease",
author = "Shoji Yamanaka and Johnson, {Mark D.} and Alex Grinberg and Heiner Westphal and Jacqueline Crawley and Masako Taniike and Kinuko Suzuki and Proia, {Richard L.}",
year = "1994",
month = "10",
day = "11",
doi = "10.1073/pnas.91.21.9975",
language = "English (US)",
volume = "91",
pages = "9975--9979",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "21",

}

TY - JOUR

T1 - Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease

AU - Yamanaka, Shoji

AU - Johnson, Mark D.

AU - Grinberg, Alex

AU - Westphal, Heiner

AU - Crawley, Jacqueline

AU - Taniike, Masako

AU - Suzuki, Kinuko

AU - Proia, Richard L.

PY - 1994/10/11

Y1 - 1994/10/11

N2 - Tay-Sachs disease, the prototype of the G(M2) gangliosidoses, is a catastrophic neurodegenerative disorder of infancy. The disease is caused by mutations in the HEXA gene resulting in an absence of the lysosomal enzyme, β-hexosaminidase A. As a consequence of the enzyme deficiency, G(M2) ganglioside accumulates progressively, beginning early in fetal life, to excessive amounts in the central nervous system. Rapid mental and motor deterioration starting in the first year of life leads to death by 2-4 years of age. Through the targeted disruption of the mouse Hexa gene in embryonic stem cells, we have produced mice with biochemical and neuropathologic features of Tay-Sachs disease. The mutant mice displayed <1% of normal β- hexosaminidase A activity and accumulated G(M2) ganglioside in their central nervous system in an age-dependent manner. The accumulated ganglioside was stored in neurons as membranous cytoplasmic bodies characteristically found in the neurons of Tay-Sachs disease patients. At 3-5 months of age, the mutant mice showed no apparent defects in motor or memory function. These β- hexosaminidase A-deficient mice should be useful for devising strategies to introduce functional enzyme and genes into the central nervous system. This model may also be valuable for studying the biochemical and pathologic changes occurring during the course of the disease.

AB - Tay-Sachs disease, the prototype of the G(M2) gangliosidoses, is a catastrophic neurodegenerative disorder of infancy. The disease is caused by mutations in the HEXA gene resulting in an absence of the lysosomal enzyme, β-hexosaminidase A. As a consequence of the enzyme deficiency, G(M2) ganglioside accumulates progressively, beginning early in fetal life, to excessive amounts in the central nervous system. Rapid mental and motor deterioration starting in the first year of life leads to death by 2-4 years of age. Through the targeted disruption of the mouse Hexa gene in embryonic stem cells, we have produced mice with biochemical and neuropathologic features of Tay-Sachs disease. The mutant mice displayed <1% of normal β- hexosaminidase A activity and accumulated G(M2) ganglioside in their central nervous system in an age-dependent manner. The accumulated ganglioside was stored in neurons as membranous cytoplasmic bodies characteristically found in the neurons of Tay-Sachs disease patients. At 3-5 months of age, the mutant mice showed no apparent defects in motor or memory function. These β- hexosaminidase A-deficient mice should be useful for devising strategies to introduce functional enzyme and genes into the central nervous system. This model may also be valuable for studying the biochemical and pathologic changes occurring during the course of the disease.

KW - animal model

KW - G(M2) gangliosidosis

KW - homologous recombination

KW - lysosomal storage disease

UR - http://www.scopus.com/inward/record.url?scp=0027959501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027959501&partnerID=8YFLogxK

U2 - 10.1073/pnas.91.21.9975

DO - 10.1073/pnas.91.21.9975

M3 - Article

VL - 91

SP - 9975

EP - 9979

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 21

ER -